Nicholas J. Short, MD, on the Future of ALL and Possibilities for Transplant in These Patients

News
Video

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

In an interview with CancerNetwork®, Nicholas J. Short, MD, of the University of Texas MD Anderson Cancer Center, explained what’s coming next for the field of acute lymphoblastic leukemia (ALL) at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

It’s important that we continue to optimize ALL regimens. And with all regimens, there is a risk of toxicity with intensive chemotherapy and with long durations of chemotherapy. It’s relatively rare in a very fit population, but there are still patients who get significant cytopenias, have major infections, or even die in remission because of the need for repetitive [therapy] cycles, at least with our current paradigms of chemotherapy. If there’s anything that we can do to identify patients who don’t need to continue with 2 to 3 years of maintenance therapy, that would be clinically important.

A big question in the field of ALL in general is, “which patients need transplant?” Obviously, transplant comes with significant morbidity and potential for mortality. If we can identify patients who don’t need a transplant in first remission, that would be important for improving long-term outcomes for these patients.

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content